Conferences
ASCO 2024: Comparison of Outcomes with Docetaxel or ARPI Combination Therapy for mHSPC by Volume of Disease
June 3, 2024
ASCO 2024: A Phase 1/2 Study of ONCT-534-101, a Dual-Action Androgen Receptor Inhibitor, in Patients with mCRPC
June 3, 2024